PETMED EXPRESS INC
Close on Oct 19, 2026
- Market cap
- $24.93M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Petmed Express
Retail-Drug Stores and Proprietary Stores, SIC 5912
PetMed Express, Inc. operates as a direct-to-consumer pet health and wellness retailer and online pharmacy. The company provides prescription medications, generic pharmaceuticals, compounded prescriptions, and over-the-counter health and wellness supplies for cats, dogs, and horses. Its catalog also includes specialized prescription diets, non-prescription pet food, treats, supplements, and related care merchandise. Through owned digital retail channels and customer contact centers, the business serves retail pet owners nationwide, while coordinating prescription authorizations directly with licensed veterinarians.
The company distributes pet health products across all 50 U.S. states and maintains pharmacy operations through two primary licensed facilities located in Lynbrook, New York, and Delray Beach, Florida. Its corporate headquarters and main distribution center are situated in Delray Beach, Florida. As of March 31, 2026, PetMed Express employed 189 full-time personnel across its operational, fulfillment, and customer support networks.
Summary of the business section of Petmed Express's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PETMED EXPRESS INC
- Founded
- 1996
- Headquarters
- Delray Beach, FL
- Address
- 420 South Congress Avenue 33445
- Phone
- (561) 426-4444
- Website
- petmeds.com
- Employees
- 189, Mar 31, 2026
- Industry
- Retail-Drug Stores and Proprietary Stores
- Incorporated in
- Florida
- Fiscal year ends
- March 31
- Auditor
- RSM US LLP, Coral Gables, Florida
Stock & identifiers
- Ticker
- PETS
- Exchange
- Nasdaq
- Shares outstanding
- 22M, Aug 7, 2026
- Public float
- $46.00M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1040130
- CUSIP
- 716382106
- ISIN
- US7163821066
- LEI
- 529900PGHW5ASJ1AZL48
- EIN
- 65-0680967
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeffrey Allen Willard | CEO and President, Director | 250,000 |
| Leslie C.G. Campbell | Interim CEO and President, Director | 175,000 |
| Sandra Yvette Campos | CEO & President, Director | 580,089 |
| Douglas Krulik | CAO and Interim CFO | 102,500 |
| Tamar Elkeles | Director | 49,923 |
| Peter Batushansky | Director | 91,928 |
| Justin L. Mennen | Director | 98,274 |
| James LaCamp | Director | 90,421 |
| Gian Fulgoni | Director | 132,299 |
| Leah Solivan | Director | 42,289 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Campbell | $830.22K | $812.99K | $469.11K | $9 | – |
| FY2026 Campos | $683.76K | -$1.53M | $469.11K | $9 | – |
| FY2025 Campos | $3.89M | $3.67M | $666.25K | $17 | – |
| FY2025 Hulett | $242.98K | $224.23K | $666.25K | $17 | – |
| FY2024 Hulett | $534.02K | -$70.18K | $635.26K | $20 | – |
| FY2024 Mr. Mathew N. Hulett | $534.02K | -$70.18K | $635.26K | $20 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had 189 full-time employees.”
Corporate history
Events identified from SEC filings